In the group of lymph node metastasis, the overall survival of FPR2+ patients was worse than that of FPR2− patients (P = 0.0145, Fig. S1C), but the overall survival of patients was not associated with FPR2 expression in the group of non-lymph node metastasis (P = 0.1909, Fig. S1D). This evidence concerns the gene FPR2 and metastatic malignant neoplasm in the lymph nodes.